RxDoctor Payments Data

Vikram Vadyala, MD

Internal Medicine · Midland, TXNPI 1497985188

Payments from drug & device makers

$421in general payments, 2019–2025

Across 20 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$140
  • Novo Nordisk$122
  • AbbVie$40
  • Lundbeck LLC$38
  • AstraZeneca$27
  • Pfizer$19
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$421 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$483,902
Medicare patients
530
Services billed
7,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide176$208,670
EliquisApixaban115$107,968
JardianceEmpagliflozin74$86,590
MounjaroTirzepatide51$54,628
TrulicityDulaglutide47$48,095
TymlosAbaloparatide12$36,581
JanuviaSitagliptin Phosphate22$31,539
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$29,692
EntrestoSacubitril/Valsartan12$24,277
MyrbetriqMirabegron30$21,368
Breo ElliptaFluticasone/Vilanterol45$20,379
Repatha SureclickEvolocumab16$11,823
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$11,721
Testosterone51$7,300
SynthroidLevothyroxine Sodium69$6,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$122$208,670176 claims
PfizerEliquis$19$107,968115 claims
Lilly USA, LLCMounjaro, Trulicity$140$102,72398 claims
AbbVieSynthroid$40$6,72769 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →